Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Pidala

Showing results (81-90 of 198) with videos related to

Pageof 20
Sort By:
Haematologica|February 26, 2015
Failure-free survival in a prospective cohort of patients with chronic graft-versus-host diseaseJeanne Palmer, Xiaoyu Chai, Paul J Martin, et al.
American Journal of Hematology|July 1, 2026
Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" TrialBetty K Hamilton, Lynn Onstad, Paul A Carpenter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2020
Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host DiseaseChiara Frairia, Maura Nicolosi, Jamie Shapiro, et al.
Blood|May 13, 2017
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host diseasePaul J Martin, Barry E Storer, Yoshihiro Inamoto, et al.
Contemporary Clinical Trials|July 22, 2024
Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host DiseaseBetty K Hamilton, Lynn Onstad, Paul A Carpenter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 10, 2011
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemiaStella Santarone, Joseph Pidala, Marta Di Nicola, et al.
Bone Marrow Transplantation|March 4, 2021
Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamideHany Elmariah, Syeda Mahrukh Hussnain Naqvi, Jongphil Kim, et al.
International Journal of Hematology|January 20, 2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complicationsJoseph Pidala, Jaime Roman-Diaz, Jongphil Kim, et al.
Blood Advances|June 4, 2020
Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantationYoshihiro Inamoto, Paul J Martin, Stephanie J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Association of Socioeconomic Status with Chronic Graft-versus-Host Disease OutcomesBetty K Hamilton, Lisa Rybicki, Sally Arai, et al.
Pageof 20

Showing results (81-90 of 198) with videos related to

Sort By:
Pageof 20
Haematologica|February 26, 2015
Failure-free survival in a prospective cohort of patients with chronic graft-versus-host diseaseJeanne Palmer, Xiaoyu Chai, Paul J Martin, et al.
American Journal of Hematology|July 1, 2026
Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" TrialBetty K Hamilton, Lynn Onstad, Paul A Carpenter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2020
Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host DiseaseChiara Frairia, Maura Nicolosi, Jamie Shapiro, et al.
Blood|May 13, 2017
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host diseasePaul J Martin, Barry E Storer, Yoshihiro Inamoto, et al.
Contemporary Clinical Trials|July 22, 2024
Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host DiseaseBetty K Hamilton, Lynn Onstad, Paul A Carpenter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 10, 2011
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemiaStella Santarone, Joseph Pidala, Marta Di Nicola, et al.
Bone Marrow Transplantation|March 4, 2021
Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamideHany Elmariah, Syeda Mahrukh Hussnain Naqvi, Jongphil Kim, et al.
International Journal of Hematology|January 20, 2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complicationsJoseph Pidala, Jaime Roman-Diaz, Jongphil Kim, et al.
Blood Advances|June 4, 2020
Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantationYoshihiro Inamoto, Paul J Martin, Stephanie J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Association of Socioeconomic Status with Chronic Graft-versus-Host Disease OutcomesBetty K Hamilton, Lisa Rybicki, Sally Arai, et al.
Pageof 20